An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06).
Emanuela RisiChiara BiagioniMatteo BenelliIlenia MigliaccioAmelia McCartneyMartina BonechiCristina GuarducciFlorentine HilbersSerena Di CosimoJens HuoberDario RomagnoliGiulia BoccaliniStefania VitaleChristos SotiriouLaura BiganzoliAngelo Di LeoLuca MalorniPublished in: Therapeutic advances in medical oncology (2019)
These results indicate RBsig may add valuable information to HER2 and HR expression, which may in turn inform treatment choices. HR+/HER2+/RBsig Low breast cancers exhibited the poorest pathological response following chemotherapy plus H. Accordingly, in such patients, endocrine therapy in combination with H and, possibly, a CDK4/6 inhibitor, may potentially prove to be a more effective treatment.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- poor prognosis
- newly diagnosed
- ejection fraction
- clinical trial
- squamous cell carcinoma
- lymph node
- prognostic factors
- randomized controlled trial
- stem cells
- cell cycle
- young adults
- early stage
- replacement therapy
- radiation therapy
- chronic kidney disease
- mesenchymal stem cells
- long non coding rna
- transcription factor
- deep learning
- copy number
- cell therapy
- social media